Detail
| LncRNA Name | CCAT2 |
| Synonyms | CCAT2, LINC00873, NCCP1 |
| Region | GRCh38_8:127400399-127402150 Sequence |
| Ensembl | ENSG00000280997 |
| RefSeq | NR_109834 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | endometrial cancer |
| ICD-0-3 | M8380/3 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | endometrial cancer tissues, cell lines (HEC-1-A and RL95-2) |
| Expression Pattern | up-regulated |
| Function Description | Knockdown of CCAT2 inhibited HEC-1-A and RL95-2 cells viability, migration, invasion, but induced apoptosis. CCAT2 was an endogenous sponge by competing for miR-216b, and miR-216b suppression alleviated CCAT2 silence-diminished cell growth and metastasis. miR-216b negatively regulated Bcl-2 and Bcl-2 could further active PTEN/PI3K/AKT and mTOR signaling pathways.patients with elevated expression of CCAT2 are prone to developing distant metastasis, and have poorer over all survival and progression-free survival. |
| Pubmed ID | 29036788 |
| Year | 2017 |
| Title | Knockdown of lncRNA CCAT2 inhibits endometrial cancer cells growth and metastasis via sponging miR-216b. |
| External Links |
| Links for CCAT2 | GenBank HGNC lncrnadb Noncode |
| Links for endometrial cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.